Multitask Learning with Convolutional Neural Networks and Vision Transformers Can Improve Outcome Prediction for Head and Neck Cancer Patients.
Cox proportional hazards
convolutional neural network
discrete-time survival models
head and neck cancer
loco-regional control
multitask learning
progression-free survival
survival analysis
tumor segmentation
vision transformer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Oct 2023
09 Oct 2023
Historique:
received:
31
08
2023
revised:
26
09
2023
accepted:
29
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Neural-network-based outcome predictions may enable further treatment personalization of patients with head and neck cancer. The development of neural networks can prove challenging when a limited number of cases is available. Therefore, we investigated whether multitask learning strategies, implemented through the simultaneous optimization of two distinct outcome objectives (multi-outcome) and combined with a tumor segmentation task, can lead to improved performance of convolutional neural networks (CNNs) and vision transformers (ViTs). Model training was conducted on two distinct multicenter datasets for the endpoints loco-regional control (LRC) and progression-free survival (PFS), respectively. The first dataset consisted of pre-treatment computed tomography (CT) imaging for 290 patients and the second dataset contained combined positron emission tomography (PET)/CT data of 224 patients. Discriminative performance was assessed by the concordance index (C-index). Risk stratification was evaluated using log-rank tests. Across both datasets, CNN and ViT model ensembles achieved similar results. Multitask approaches showed favorable performance in most investigations. Multi-outcome CNN models trained with segmentation loss were identified as the optimal strategy across cohorts. On the PET/CT dataset, an ensemble of multi-outcome CNNs trained with segmentation loss achieved the best discrimination (C-index: 0.29, 95% confidence interval (CI): 0.22-0.36) and successfully stratified patients into groups with low and high risk of disease progression (p=0.003). On the CT dataset, ensembles of multi-outcome CNNs and of single-outcome ViTs trained with segmentation loss performed best (C-index: 0.26 and 0.26, CI: 0.18-0.34 and 0.18-0.35, respectively), both with significant risk stratification for LRC in independent validation (p=0.002 and p=0.011). Further validation of the developed multitask-learning models is planned based on a prospective validation study, which has recently completed recruitment.
Identifiants
pubmed: 37835591
pii: cancers15194897
doi: 10.3390/cancers15194897
pmc: PMC10571894
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Comput Biol Med. 2020 Nov;126:104037
pubmed: 33065387
Insights Imaging. 2020 Aug 12;11(1):91
pubmed: 32785796
Sci Rep. 2019 Jan 24;9(1):614
pubmed: 30679599
Med Image Anal. 2022 Jan;75:102299
pubmed: 34814058
Br J Cancer. 2013 Mar 5;108(4):784-90
pubmed: 23385733
Sci Rep. 2019 Nov 21;9(1):17286
pubmed: 31754135
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
IEEE J Biomed Health Inform. 2022 Sep;26(9):4497-4507
pubmed: 35696469
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
EClinicalMedicine. 2021 Dec 09;42:101201
pubmed: 34917908
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
PLoS Med. 2018 Nov 30;15(11):e1002711
pubmed: 30500819
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Biol Cybern. 1980;36(4):193-202
pubmed: 7370364
BMC Med Res Methodol. 2022 Jul 26;22(1):207
pubmed: 35883032
PLoS One. 2014 Jan 06;9(1):e84483
pubmed: 24400093
PeerJ. 2019 Jan 25;7:e6257
pubmed: 30701130
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2970-E2979
pubmed: 29531073
Sci Rep. 2017 Aug 31;7(1):10117
pubmed: 28860628
Med Image Anal. 2022 Apr;77:102336
pubmed: 35016077
Bioinformatics. 2008 Oct 1;24(19):2200-8
pubmed: 18635567
Bioinformatics. 2011 Nov 15;27(22):3206-8
pubmed: 21903630
Sci Rep. 2017 Oct 16;7(1):13206
pubmed: 29038455
Comput Methods Programs Biomed. 2022 Jun;219:106750
pubmed: 35381490
Neuroimage. 2020 Mar;208:116459
pubmed: 31837471
BMC Med Res Methodol. 2018 Feb 26;18(1):24
pubmed: 29482517
Nat Commun. 2021 Mar 25;12(1):1851
pubmed: 33767170
Med Image Anal. 2019 Dec;58:101539
pubmed: 31374449
Sci Rep. 2020 Sep 24;10(1):15625
pubmed: 32973220
Med Phys. 2018 Jul;45(7):3449-3459
pubmed: 29763967
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
PLoS Comput Biol. 2018 Apr 10;14(4):e1006076
pubmed: 29634719